Systemic sclerosis & Raynaud's
Longitudinal Autoantibody and Proteomic Signatures of Disease Progression in Systemic Sclerosis
Authors' conclusion
Dynamic changes in autoantibody titers, rather than baseline levels, were more strongly associated with SSc trajectory. Proteomic signatures suggest lipid metabolism and oxidative stress as potential drivers
Study context
- Population
- Treatment-naïve patients with systemic sclerosis (SSc)
- Participants
- 30 / 49 / 38
- Exposure
- Patients with SSc vs controls; rising vs decreasing autoantibody titers
- SSc baselinen = 30
- SSc follow-upn = 49
- Controlsn = 38reference
- Outcome
- Disease progression in association with dynamic changes in autoantibody and proteomic profiles
Methodological detailsautoantigen microarray (120 autoantibodies), liquid chromatography mass spectrometry, data-independent acquisition, Cox proportional hazards models, Spearman's correlation
- Autoantigen microarray (120 autoantibodies)
- Liquid chromatography mass spectrometry, data-independent acquisition
- Cox proportional hazards models
- Spearman's correlation
Main finding
As reported in the abstract
Disease progression by autoantibody titer change
Patients with rising autoantibody titers who experienced disease progression
88.9%
Patients with decreasing titers who showed clinical improvement
60%
Increased CENP-B titers, strongly linked to disease progression (HR)
5.036
Observational data: associations, not effects.
Further findings
Proteomic signatures
- Proteins involved in tissue repair and immune modulation in patients with declining titers and clinical improvement
- 112
- Proteins linked to lipid metabolism and oxidative stress enriched in those with rising titers and disease progression
- 46
- SERPINA10 strongest risk factor for progression; ENTPD5 most protective
- Antibody-protein correlations identified, including SERPINE1 and muscarinic receptor antibodies
Original publication
Longitudinal Autoantibody and Proteomic Signatures of Disease Progression in Systemic Sclerosis. Arthritis Rheumatol. Published 21 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →